Zhao Zhijing, Higashi Kenjirou, Ueda Keisuke, Moribe Kunikazu
Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan.
Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan.
Int J Pharm. 2021 Sep 25;607:120984. doi: 10.1016/j.ijpharm.2021.120984. Epub 2021 Aug 11.
Probucol (PBC)/hypromellose (HPMC)/sodium dodecyl sulfate (SDS) ternary solid dispersions (SDs) of various weight ratios were prepared and evaluated to unveil the effect of HPMC and SDS on the formation of amorphous PBC nanoparticles. The morphological variation of the PBC nanoparticles prepared using SDs of different compositions was determined using dynamic light scattering and cryogenic transmission electron microscopy (cryo-TEM). Statistical analysis of particle size versus roundness of PBC nanoparticles was carried out based on cryo-TEM images. A clear correlation was observed between the morphologies of the PBC nanoparticles and the amounts of HPMC and SDS, either admixed in SDs or pre-dissolved in an aqueous solution. The admixed HPMC in SDs was demonstrated to play the major role in determining the primary particle sizes of discrete amorphous PBC nanoparticles. Based on C solid-state NMR spectroscopy, this phenomenon should be due to the enlarged size of the PBC-rich domains in SDs, which depended on the decreasing amounts of admixed HPMC. Although the pre-dissolved part of HPMC had less impact on the primary particle sizes, it was found to inhibit the particle agglomeration and recrystallization of amorphous PBC nanoparticles. On the other hand, sufficient SDS admixed in SDs could suppress the size enhancement of the PBC-rich domains during water immersion and nanoparticle evolution (agglomeration and crystallization) after aqueous dispersion. The pre-dissolved SDS could restrain the agglomeration of amorphous PBC nanoparticles, ultimately forming hundreds of irregular nanometer-order structures. Since the increase in size during water immersion, their sizes were still slightly larger than those obtained with a high portion of admixed SDS. The findings of this study clarified the usefulness and necessity of adding polymers and surfactants to SDs to fabricate drug nanoparticle formulations.
制备了不同重量比的普罗布考(PBC)/羟丙甲纤维素(HPMC)/十二烷基硫酸钠(SDS)三元固体分散体(SDs)并进行评估,以揭示HPMC和SDS对无定形PBC纳米颗粒形成的影响。使用动态光散射和低温透射电子显微镜(cryo-TEM)确定了使用不同组成的SDs制备的PBC纳米颗粒的形态变化。基于cryo-TEM图像对PBC纳米颗粒的粒径与圆度进行了统计分析。观察到PBC纳米颗粒的形态与SDs中混合的或预先溶解在水溶液中的HPMC和SDS的量之间存在明显的相关性。结果表明,SDs中混合的HPMC在决定离散无定形PBC纳米颗粒的初级粒径方面起主要作用。基于C固态核磁共振光谱,这种现象应归因于SDs中富含PBC的区域尺寸增大,这取决于混合HPMC量的减少。虽然预先溶解的HPMC部分对初级粒径的影响较小,但发现它能抑制无定形PBC纳米颗粒的颗粒团聚和重结晶。另一方面,SDs中充分混合的SDS可以抑制富PBC区域在水浸过程中的尺寸增大以及水分散后纳米颗粒的演变(团聚和结晶)。预先溶解的SDS可以抑制无定形PBC纳米颗粒的团聚,最终形成数百个不规则的纳米级结构。由于在水浸过程中尺寸增加,它们的尺寸仍然略大于使用高比例混合SDS获得的尺寸。本研究结果阐明了向SDs中添加聚合物和表面活性剂以制备药物纳米颗粒制剂的实用性和必要性。